Bausch Health Companies Inc. (BHC)
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Bausch Health Companies Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | 8.43 | 8.85 | 8.41 | 8.73 | 7,062,107 |
| Nov 17, 2026 | 8.39 | 8.48 | 8.21 | 8.47 | 2,702,689 |
| Nov 16, 2026 | 8.34 | 8.57 | 8.34 | 8.42 | 3,819,039 |
| Nov 13, 2026 | 8.25 | 8.40 | 8.18 | 8.35 | 2,340,417 |
| Nov 12, 2026 | 8.36 | 8.43 | 8.24 | 8.25 | 2,350,370 |
| Nov 11, 2026 | 8.29 | 8.46 | 8.20 | 8.35 | 2,401,051 |
| Nov 10, 2026 | 8.39 | 8.39 | 8.15 | 8.29 | 2,450,866 |
| Nov 9, 2026 | 8.19 | 8.56 | 8.19 | 8.40 | 3,952,086 |
| Nov 6, 2026 | 7.86 | 8.20 | 7.86 | 8.18 | 3,067,557 |
| Nov 5, 2026 | 8.34 | 8.38 | 7.96 | 7.96 | 3,344,721 |
| Nov 4, 2026 | 8.28 | 8.46 | 8.22 | 8.34 | 3,529,976 |
| Nov 3, 2026 | 7.96 | 8.18 | 7.87 | 8.14 | 3,422,162 |
| Nov 2, 2026 | 8.21 | 8.35 | 7.96 | 8.02 | 4,943,345 |
| Oct 30, 2026 | 8.93 | 9.04 | 8.18 | 8.20 | 8,868,424 |
| Oct 29, 2026 | 7.66 | 9.04 | 7.58 | 8.91 | 33,781,852 |
| Oct 28, 2026 | 6.29 | 6.97 | 6.25 | 6.92 | 8,073,976 |
| Oct 27, 2026 | 6.37 | 6.37 | 6.22 | 6.31 | 1,562,813 |
| Oct 26, 2026 | 6.53 | 6.55 | 6.27 | 6.35 | 2,401,570 |
| Oct 23, 2026 | 6.44 | 6.49 | 6.20 | 6.44 | 2,427,285 |
| Oct 22, 2026 | 6.43 | 6.50 | 6.41 | 6.49 | 1,196,581 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Grant/Award | 5.8K | $33.7K | Sep 30, 2026 | |
| Director | Grant/Award | 1.2K | $6.9K | Sep 30, 2026 | |
| Director | Grant/Award | 10.7K | $62.5K | Sep 30, 2026 | |
| President, US Pharma | Sale | 36.8K | $258.9K | Aug 19, 2026 | |
| President, US Pharma | Automatic Sell | 5.3K | $25.4K | Jul 17, 2026 | |
| President, US Pharma | Automatic Sell | 23.4K | $114.4K | Jul 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
PAULSON & CO. INC. | 73.3M | 19.6% | 13F |
GOLDENTREE ASSET MANAGEMENT LP | 34.7M | 9.3% | 13F |
NOMURA HOLDINGS INC · also on 13F· may incl. warrants· filed Nov 2025 | 15.7M | 4.2% | 13G |
ROYAL BANK OF CANADA | 9.2M | 2.5% | 13F |
GOLDMAN SACHS GROUP INC | 7.7M | 2.1% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | 2.0% | 13F |
TWO SIGMA INVESTMENTS, LP | 7.4M | 2.0% | 13F |
ACADIAN ASSET MANAGEMENT LLC | 7.2M | 1.9% | 13F |
MFN Partners Management, LP | 6.0M | 1.6% | 13F |
SG Americas Securities, LLC | 5.5M | 1.5% | 13F |
Insiders
- LEUNG SANDRADirector
- WECHSLER AMY BDirector
- Paulson JohnDirector
- Lenar Aimee J.President, US Pharma
- LEE STEVEN HYOSIGSVP, Controller & CAO
- GOETTLER MICHAELDirector
- Garcia Christian ADirector
- KAVANAGH SARAH BDirector
- Lee Frank D.Director
- POWER ROBERT NDirector
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies.
Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S.
The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018.
Its corporate headquarters are located in Laval, Canada.
based on 374.27M shares outstanding
30d Avg
4.90M
60d Avg
3.39M
90d Avg
3.17M
Bausch Health Companies Inc. (NYSE: BHC) traded at $8.73 on Nov 18, 2026, up 3.07% from the previous close of $8.47. The company is in the Healthcare sector (Drug Manufacturers - Specialty & Generic).